Logo image of CWEB.CA

CHARLOTTES WEB HOLDINGS INC (CWEB.CA) Stock Fundamental Analysis

TSX:CWEB - Toronto Stock Exchange - CA16106R1091 - Common Stock - Currency: CAD

0.125  0 (0%)

Fundamental Rating

1

Overall CWEB gets a fundamental rating of 1 out of 10. We evaluated CWEB against 34 industry peers in the Pharmaceuticals industry. CWEB may be in some trouble as it scores bad on both profitability and health. CWEB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year CWEB has reported negative net income.
CWEB had a negative operating cash flow in the past year.
CWEB had negative earnings in each of the past 5 years.
CWEB had a negative operating cash flow in each of the past 5 years.
CWEB.CA Yearly Net Income VS EBIT VS OCF VS FCFCWEB.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

CWEB has a Return On Assets (-26.31%) which is in line with its industry peers.
CWEB's Return On Equity of -110.19% is on the low side compared to the rest of the industry. CWEB is outperformed by 70.59% of its industry peers.
Industry RankSector Rank
ROA -26.31%
ROE -110.19%
ROIC N/A
ROA(3y)-24.53%
ROA(5y)-32.75%
ROE(3y)-76.52%
ROE(5y)-69.45%
ROIC(3y)N/A
ROIC(5y)N/A
CWEB.CA Yearly ROA, ROE, ROICCWEB.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

1.3 Margins

CWEB has a Gross Margin (42.81%) which is comparable to the rest of the industry.
CWEB's Gross Margin has declined in the last couple of years.
CWEB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.81%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.4%
GM growth 5Y-4.67%
CWEB.CA Yearly Profit, Operating, Gross MarginsCWEB.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

2

2. Health

2.1 Basic Checks

CWEB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CWEB has more shares outstanding
Compared to 5 years ago, CWEB has more shares outstanding
The debt/assets ratio for CWEB is higher compared to a year ago.
CWEB.CA Yearly Shares OutstandingCWEB.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
CWEB.CA Yearly Total Debt VS Total AssetsCWEB.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -3.79, we must say that CWEB is in the distress zone and has some risk of bankruptcy.
CWEB's Altman-Z score of -3.79 is on the low side compared to the rest of the industry. CWEB is outperformed by 67.65% of its industry peers.
A Debt/Equity ratio of 1.61 is on the high side and indicates that CWEB has dependencies on debt financing.
CWEB's Debt to Equity ratio of 1.61 is on the low side compared to the rest of the industry. CWEB is outperformed by 85.29% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.61
Debt/FCF N/A
Altman-Z -3.79
ROIC/WACCN/A
WACC6.62%
CWEB.CA Yearly LT Debt VS Equity VS FCFCWEB.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

CWEB has a Current Ratio of 2.95. This indicates that CWEB is financially healthy and has no problem in meeting its short term obligations.
CWEB's Current ratio of 2.95 is fine compared to the rest of the industry. CWEB outperforms 70.59% of its industry peers.
CWEB has a Quick Ratio of 1.76. This is a normal value and indicates that CWEB is financially healthy and should not expect problems in meeting its short term obligations.
CWEB's Quick ratio of 1.76 is fine compared to the rest of the industry. CWEB outperforms 67.65% of its industry peers.
Industry RankSector Rank
Current Ratio 2.95
Quick Ratio 1.76
CWEB.CA Yearly Current Assets VS Current LiabilitesCWEB.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

1

3. Growth

3.1 Past

The earnings per share for CWEB have decreased strongly by -21.82% in the last year.
Looking at the last year, CWEB shows a very negative growth in Revenue. The Revenue has decreased by -21.36% in the last year.
The Revenue for CWEB have been decreasing by -12.09% on average. This is quite bad
EPS 1Y (TTM)-21.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.19%
Revenue 1Y (TTM)-21.36%
Revenue growth 3Y-19.75%
Revenue growth 5Y-12.09%
Sales Q2Q%-20.06%

3.2 Future

The Earnings Per Share is expected to grow by 28.45% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y60%
EPS Next 2Y28.45%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year7.9%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CWEB.CA Yearly Revenue VS EstimatesCWEB.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
CWEB.CA Yearly EPS VS EstimatesCWEB.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.1 -0.1 -0.2 -0.3

1

4. Valuation

4.1 Price/Earnings Ratio

CWEB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CWEB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CWEB.CA Price Earnings VS Forward Price EarningsCWEB.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CWEB.CA Per share dataCWEB.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as CWEB's earnings are expected to grow with 28.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.45%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

CWEB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

CHARLOTTES WEB HOLDINGS INC

TSX:CWEB (4/29/2025, 7:00:00 PM)

0.125

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-19 2025-03-19/amc
Earnings (Next)05-06 2025-05-06
Inst Owners2.28%
Inst Owner ChangeN/A
Ins Owners9.62%
Ins Owner ChangeN/A
Market Cap19.75M
Analysts82.86
Price Target0.51 (308%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-15.75%
Min Revenue beat(2)-26.52%
Max Revenue beat(2)-4.98%
Revenue beat(4)0
Avg Revenue beat(4)-14.65%
Min Revenue beat(4)-26.52%
Max Revenue beat(4)-4.98%
Revenue beat(8)0
Avg Revenue beat(8)-18.51%
Revenue beat(12)0
Avg Revenue beat(12)-18.89%
Revenue beat(16)0
Avg Revenue beat(16)-18.2%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)38.46%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.29
P/FCF N/A
P/OCF N/A
P/B 0.53
P/tB 1.16
EV/EBITDA N/A
EPS(TTM)-0.26
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0.44
BVpS0.24
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.31%
ROE -110.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.81%
FCFM N/A
ROA(3y)-24.53%
ROA(5y)-32.75%
ROE(3y)-76.52%
ROE(5y)-69.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.4%
GM growth 5Y-4.67%
F-Score2
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 1.61
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.59%
Cap/Sales 7.75%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.95
Quick Ratio 1.76
Altman-Z -3.79
F-Score2
WACC6.62%
ROIC/WACCN/A
Cap/Depr(3y)21.98%
Cap/Depr(5y)104.62%
Cap/Sales(3y)4.65%
Cap/Sales(5y)9.75%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.19%
EPS Next Y60%
EPS Next 2Y28.45%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-21.36%
Revenue growth 3Y-19.75%
Revenue growth 5Y-12.09%
Sales Q2Q%-20.06%
Revenue Next Year7.9%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year45.76%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-31.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.18%
OCF growth 3YN/A
OCF growth 5YN/A